Subarachnoid Hemorrhage is Followed by Pituitary Gland Volume Loss: A Volumetric MRI Observational Study

Verena Rass1, Elisabeth Schoenherr2, Bogdan-Andrei Ianosi1,3, Anna Lindner1, Mario Kofler1, Alois J. Schiefecker1, Lukas Lenhart4, Max Gaasch1, Marie-Theres Pertl1, Christian F. Freyschlag5, Bettina Pfaußler1, Margarete Delazer1, Ronny Beer1, Claudius Thomé5, Astrid Ellen Grams4, Christoph Scherfler1 and Raimund Helbok1*

© 2019 The Author(s)

Abstract

Background: Subarachnoid hemorrhage (SAH) is a devastating disease associated with high mortality and morbidity. Besides neurological sequelae, neuropsychological deficits largely contribute to patients' long-term quality of life. Little is known about the pituitary gland volume (PGV) after SAH compared to healthy referents and the association of PGV with long-term outcome including cognitive function.

Methods: Sixty consecutive non-traumatic SAH patients admitted to the neurological intensive care unit between 2010 and 2014 were enrolled. 3-Tesla magnetic resonance imaging was performed at baseline (16 days) and 12 months after SAH to measure PGV semi-automatically using the software iPlan Net 3.5.0. PGV was compared to age and sex matched healthy referents. The difference between baseline and 1-year-PGV was classified as increase (> 20 mm³ PGV increase), stable (± 20 mm³), or decrease (> 20 mm³ PGV decrease). In addition, total intracerebral volume was calculated. Neuropsychological testing was applied in 43 SAH patients at 1-year follow up encompassing several domains (executive, attention, memory) and self-assessment (questionnaire for self-perceived deficits in attention [German: FEDA]) of distractibility in mental processes, fatigue and decrease in motivation. Multivariable regression with multivariable generalized linear models was used for comparison of PGVs and for subgroup analysis to evaluate a potential association between PGV and neuropsychological outcome.

Results: Patients were 53 years old (IQR = 44–63) and presented with a median Hunt&Hess grade of 2 (IQR = 1–3). SAH patients had a significantly lower PGV both at baseline (360 ± 19 mm³, p < 0.001) and 1 year (367 ± 18 mm³ p < 0.001) as compared to matched referents (mean 505 ± 18 mm³). PGV decreased by 75 ± 8 mm³ in 28 patients, increased by 120 ± 22 mm³ in 22 patients and remained stable in 10 patients at 1-year follow-up. PGV in patients with PGV increase at 12 months was not different to healthy referents (p = 0.062). Low baseline PGV was associated with impaired executive functions at 1 year (adjOR = 8.81, 95%-CI = 1.46–53.10, p = 0.018) and PGV decrease within 1 year was associated with self-perceived worse motivation (FEDA; Wald-statistic = 6.6, df = 1, p = 0.010).

*Correspondence: raimund.helbok@tirol-kliniken.at; raimund.helbok@i-med.ac.at
1 Department of Neurology, Neurocritical Care Unit, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
Full list of author information is available at the end of the article
Introduction
Subarachnoid hemorrhage (SAH) is a devastating disease still being associated with a high mortality and morbidity. Despite improved survival rates due to advances in the individualized neurocritical care management [1], quality of life is strongly diminished in a substantial number of SAH survivors [2]. Although many patients are classified as having a favorable functional outcome, neuropsychological and cognitive deficits are common. This includes decreased executive functions and memory impairments, as well as emotional deficits such as depression, anxiety and fatigue [2]. While it is well known that the bleeding itself and hospital complications substantially contribute to these deficits [2, 3], early identification of patients at high risk remains difficult. Some of the typical neuropsychological deficits after SAH resemble clinical symptoms of hypopituitarism [4], which is commonly observed in the acute and subacute phase after SAH [5–8]. Potential pathophysiological mechanisms resulting in endocrine dysfunction include direct compression of the hypothalamic-pituitary complex by the aneurysm itself, intracranial hypertension, compromised perfusion during initial circulatory arrest after SAH with subsequent ischemic injury, hydrocephalus, and iatrogenic causes through pharmacological treatment or procedure related injuries [5, 9].

Pituitary gland volume (PGV) assessed in the subacute phase after SAH may be an adequate radiological biomarker to identify patients at high risk for subsequent deficits resembling endocrine dysfunctions. To the best of our knowledge there are no studies on PGV after SAH. Following traumatic brain injury (TBI) PGV increased soon after and normalized within 1 year to a volume comparable to healthy age and sex matched referents [10]. Moreover, pituitary imaging abnormalities were related to hypopituitarism after TBI [11]. In line with this observation, hypopituitarism in SAH patients was linked to hypothalamic magnetic resonance imaging (MRI) lesions [12]. Several radiographic parameters including global cerebral edema, left-sided infarction [3, 13] and focal lesions [14] have been associated with impaired neuropsychological test performance following SAH. In long-term, regional and global brain atrophy have been correlated with cognitive deficits after SAH [15–19].

In the current study we hypothesized, that atrophy of the pituitary gland occurs after SAH and may be associated with neuropsychological impairments. Therefore, we aimed (1) to quantify the PGV at baseline and at 1-year follow-up in comparison with healthy referents, (2) to assess disease related and demographic factors associated with decreased PGV after SAH and (3) to associate PGV in the subacute and chronic phase with neuropsychological outcome parameters.

Methods
Study Design, Setting and Participants
The study design was guided by the STROBE statement on observational cohort studies. We screened 183 consecutive patients with non-traumatic SAH admitted to the neurological intensive care unit (ICU) of a tertiary hospital (Medical University of Innsbruck) between April 2010 and December 2014. Out of these, 79 patients met the following inclusion criteria: (1) age greater or equal to 18 years, (2) ICU stay for more than 24 h, (3) baseline and 1-year follow-up MRI-scan, (4) exclusion of arteriovenous-malformation. Further radiological exclusion criteria encompassed (1) patients with macroadenoma (N = 1), (2) artifacts not compatible with volumetric PGV analysis (N = 6) and (3) missing sequences for volumetric PGV quantification (N = 12) leaving 60 patients eligible for final analysis of this observational study. Approval for this study was granted by the local ethics committee (Medical University of Innsbruck, AM4091-292/4.6). All patients gave informed consent according to local regulations in accordance with the Declaration of Helsinki.

Clinical Management
Clinical management of patients after SAH conformed to international guidelines [20, 21]. Ruptured aneurysms were occluded by either clipping or coiling. Oral or intravenous nimodipine was administered prophylactically in all patients. All patients were followed for vasospasm with repetitive transcranial color coded duplex sonography (TCD, LOGIQ S8, GE Healthcare, Chicago, Illinois, United States). Vasospasm was defined as an elevation of mean velocities > 120 cm/s in the middle or anterior cerebral artery or a daily change in mean TCD-velocities > 50 cm/s. Severe vasospasm (> 200 cm/s) was further confirmed by catheter cerebral angiogram.
and nimodipine was administered intraarterial. Delayed cerebral ischemia was defined as clinical deterioration (decrease of ≥ 2 points on the Glasgow Coma Scale), occurrence of a new focal neurological deficit or a new infarction on computed tomography or MRI-scan not attributable to other causes [22]. The treatment of intracranial hypertension included osmotherapy with mannitol (15%) or hypertonic saline (10%) infusions. fT3, fT4 and TSH levels were routinely measured at admission and further during ICU stay following clinical necessity. Cortisol levels were measured in all patients with refractory hypotension or high need of catecholaminergic support. Patients’ baseline characteristics, complications and outcomes were prospectively collected in weekly meetings held by the study team and treating neurointensivists.

MRI Data Acquisition and Image Postprocessing for Volumetric Analysis

MRI-scans of the brain were performed on a 3-Tesla whole-body MRI scanner (Magnetom Verio, Siemens Erlangen, Germany) using a 12-channel head coil at baseline (16 days) and 12 months after SAH. The MRI protocol was identical in all patients and included whole-brain T1-weighted, and fluid-attenuated inversion recovery, T2- and proton density-weighted. MRI sequences for coronal T1-weighted 3D magnetization prepared rapid gradient echo were: repetition time (TR) = 1800 ms; echo time (TE) = 2.18 ms; inversion time, TI = 900 ms; slice thickness: 1.2 mm; matrix: 384 × 512; number of excitations: 1; flip angle = 9°; field of view 220 × 165 mm.

PGVs were semi-automatically measured using the software iPlan Net 3.5.0 (Brainlab AG, Germany; Fig. 1) by ES. Coronal T1-weighted whole-brain sequences were selected, and the pituitary gland brushed on each slice before starting the segmentation. Pituitary volumes were obtained in cubic millimeters. Total intracranial volume (TIV) was calculated by segmenting and summing up the gray and white matter as well as cerebrospinal fluid compartments using the software package statistical parametric mapping (SPM12, Wellcome Department of Cognitive Neurology, London, UK) implemented in Matlab 9.2 (Mathworks Inc., Sherborn, MA). To assess interrater reliability, the PGV of 20 patients was assessed by a second independent rater (AG), blinded to clinical data and the volumetric results.

Quantified volumes were compared to 60 age and sex matched healthy referents selected from the MRI database of the Department of Neuroradiology, Medical University of Innsbruck.

![Fig. 1 a] Semiautomatic pituitary volumetry with the software iPlan Net showing 3 planes: b transverse, c sagittal and d coronal
Neuropsychological and Outcome Evaluation

Functional neurological outcome was assessed at 3 months by a study nurse blinded to the disease course of the patient and at 12 months by a medical doctor of the study team and rated with the modified Rankin Scale score (mRS). Unfavorable outcome was defined as mRS ≥ 3.

Additionally, neuropsychological in-person assessment was applied in 49 patients at 12 months after ictus, 43 completed all tests relevant for the current analysis. Several cognitive domains (executive, attention, orientation, verbal and visual memory, language and visual-spatial skills) were screened using a standardized test battery. Furthermore, questionnaires for symptoms of anxiety and depression [23] as well as the German Questionnaire for self-perceived deficits in attention, or FEDA (including 3 domains: distractibility in mental processes, fatigue and decrease in motivation) [24] were used. Screening of global cognitive functions was done by the Mini-Mental State Examination [25]. Several executive functions were evaluated by validated tests, including semantic verbal fluency (number of named animals within 60 s) by the Regensburg test, as appropriate. The difference between baseline and follow-up PGV was coded as increase (>20 mm³ PGV increase), stable (±20 mm³), or decrease (>20 mm³ PGV decrease), based on the observation of a mean error of 21 mm³ (±8) assessed in 3 control groups. Within-patient variations of PGV normalized to ΔTIV over 1 year were compared using the paired t test.

Multivariable generalized linear models were used to identify associations between relative PGVs (PGV_{SAH}/PGV_{REF}^100) or ΔPGV (PGV_{FU}−PGV_{baseline} in SAH patients) and scores of neuropsychological tests including the FAB score (continuous variable) and FEDA questionnaire (continuous variable). For the multivariable model associating PGV with FAB, clinically important variables were entered along with potential confounders (education years, sex, age, H&H grade). All models were adjusted for TIV. Cases with missing values were included. All analyses and graphical representations were performed with SPSS (IBM SPSS Statistics, Version 24.0. Armonk, NY, USA). Statistical significance was attributed to a p value <0.05.

Results

Baseline Characteristics

A total of 60 patients were included in final analysis. The median age was 53 (IQR = 44–63) years and 37 patients (62%) were women. The full spectrum of clinical severity grades of SAH patients was analyzed: twenty-one (35%) patients presented with an admission H&H grade of 1, 18 (30%) with 2, 9 (15%) with 3, 2 (3%) with 4 and 10 (17%) patients with a H&H grade of 5. Detailed information on admission variables and hospital complications is given in Table 1. Age (p = 0.972) and sex (p = 1.00) were not significantly different between SAH patients and healthy referents.

MRI-scans were obtained at a median interval of 16 (IQR = 14–25) and 385 (IQR = 372–395) days after SAH. Nineteen patients (32%) had low cortisol levels together with a high catecholamine demand, prompting continuous hydrocortisone administration with a cumulative dose of 923 mg (IQR = 623–1308, assessed within the first 15 days of admission). Routinely measured levels of TSH, fT4 and fT3 in 55 patients revealed 3 patients (6%) with latent hyperthyroidism, 1 patient (2%) with manifest hyperthyroidism, 9 (16%) with latent hypothyroidism and 42 (76%) with normal thyroid gland function during ICU stay. In 7 patients oral thyroxin was administered during ICU stay, whereas at 1-year FU 5 patients still required thyroxin.

PGV and Its Dynamic Change in SAH Patients Compared to Healthy Referents

Interobserver reliability of PGV was high with an intraclass correlation coefficient (ICC) of 0.979. PGV was
Table 1  Risk factors for low pituitary gland volume in 60 SAH patients relative to healthy referents

| Clinical characteristics | Baseline | | | | | | 1-year follow-up | | | |
| | Low PGV | High PGV | P value | Low PGV | High PGV | P value | | | | |
| Age (years) | 53 (44–63) | 58 (49–66) | 49 (40–60) | **0.011** | 56 (46–63) | 50 (41–64) | 0.376 | | | |
| Female gender | 37 (62) | 20 (67) | 17 (57) | 0.596 | 18 (60) | 19 (63) | 1.0 | | | |
| Admission Hunt and Hess grade | 2 (1–3) | 2 (1–3) | 2 (2–3) | 0.173 | 2 (1–3) | 2 (1–3) | 0.288 | | | |
| Admission GCS | 15 (8–15) | 15 (10–15) | 15 (3–15) | 0.305 | 15 (10–15) | 15 (4–15) | 0.581 | | | |
| Hypertension history | 24 (40) | 16 (53) | 8 (27) | 0.064 | 13 (43) | 11 (37) | 0.792 | | | |
| Diabetes mellitus | 2 (3) | 2 (7) | 0 (0) | 0.492 | 2 (7) | 0 (0) | 0.492 | | | |
| Admission glucose in mg/dL | 121 (109–149) | 126 (110–162) | 117 (109–145) | 0.464 | 119 (109–152) | 121 (110–150) | 0.836 | | | |
| Loss of consciousness at ictus | 14 (23) | 6 (20) | 8 (27) | 0.761 | 6 (20) | 8 (27) | 0.761 | | | |
| Admission radiological characteristics | | | | | | | | | | |
| Modified Fisher at admission | 3 (2–4) | 3 (2–4) | 3 (2–4) | 0.482 | 3 (3–4) | 3 (2–4) | 0.574 | | | |
| ICH on admission | 9 (15) | 3 (10) | 6 (20) | 0.472 | 5 (17) | 4 (13) | 0.731 | | | |
| Hydrocephalus requiring EVD | 18 (30) | 8 (27) | 10 (33) | 0.779 | 7 (23) | 11 (37) | 0.399 | | | |
| Aneurysm size | 5 (3–8) | 5 (3–8) | 5 (3–9) | 0.752 | 5 (3–8) | 5 (3–9) | 0.929 | | | |
| Aneurysm localization | | | | | | | | | | |
| ACA, ACoA | 25 (42) | 14 (64) | 11 (55) | 0.754 | 14 (61) | 11 (58) | 1.00 | | | |
| ICA, MCA | 9 (15) | 3 (14) | 6 (30) | 0.269 | 4 (17) | 5 (26) | 0.707 | | | |
| Posterior circulation | 8 (13) | 5 (23) | 3 (15) | 0.700 | 5 (22) | 3 (16) | 0.709 | | | |
| Admission SEBES | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0.815 | 1 (0–2) | 1 (0–2) | 0.512 | | | |
| Brain compartments at baseline MRI | | | | | | | | | | |
| Total intracerebral volume in ccm | 1409 ± 19 | 1376 ± 26 | 1443 ± 26 | 0.076 | 1408 ± 25 | 1434 ± 28 | 0.483 | | | |
| Gray matter in ccm | 656 ± 10 | 639 ± 12 | 673 ± 17 | 0.107 | 635 ± 12 | 632 ± 19 | 0.966 | | | |
| White matter in ccm | 416 ± 9 | 406 ± 10 | 426 ± 15 | 0.266 | 397 ± 10 | 403 ± 15 | 0.765 | | | |
| Cerebrospinal fluid in ccm | 337 ± 13 | 330 ± 16 | 344 ± 20 | 0.608 | 377 ± 18 | 400 ± 23 | 0.709 | | | |
| Aneurysm treatment | | | | | | | | | | |
| Coiling | 28 (47) | 17 (57) | 11 (37) | 0.192 | 16 (53) | 12 (40) | 0.748 | | | |
| Clipping | 14 (23) | 5 (17) | 9 (30) | 0.192 | 7 (23) | 7 (23) | 0.748 | | | |
| Non-aneurysmal SAH | 18 (30) | 8 (30) | 10 (33) | 0.779 | 7 (23) | 11 (37) | 0.399 | | | |
| Hospital complications | | | | | | | | | | |
| Pneumonia | 23 (38) | 11 (37) | 12 (40) | 1.00 | 10 (33) | 13 (43) | 0.596 | | | |
| Ventriculitis | 6 (8) | 3 (10) | 2 (7) | 0.00 | 2 (7) | 2 (7) | 1.00 | | | |
| Urinary tract infection | 16 (27) | 9 (30) | 7 (24) | 0.771 | 7 (23) | 9 (31) | 0.567 | | | |
| Hyponatremia (< 130 mmol/L)² | 12 (20) | 5 (17) | 7 (23) | 0.748 | 7 (23) | 5 (17) | 0.748 | | | |
| Hypertension (> 150 mmol/L)² | 7 (12) | 3 (10) | 4 (13) | 1.00 | 4 (13) | 3 (10) | 1.00 | | | |
| Peak leukocytes² | 14.2 (11.0–17.8) | 14.6 (10.7–18.1) | 13.9 (12.1–17.9) | 0.841 | 14.5 (7.0–24.0) | 13.9 (11.2–17.9) | 0.950 | | | |
| Fever > 38.3 °C | 31 (53) | 14 (47) | 17 (61) | 0.306 | 14 (47) | 17 (61) | 0.306 | | | |
| Hydrocortison, cumulative dose in mg² | 0 (0–623) | 0 (0–161) | 0 (0–826) | 0.173 | 0 (0–161) | 0 (0–826) | 0.102 | | | |
| Vasospasm | 29 (48) | 16 (53) | 13 (43) | 0.606 | 14 (47) | 15 (50) | 1.00 | | | |
| Delayed cerebral ischemia | 15 (25) | 8 (27) | 7 (23) | 1.00 | 8 (27) | 7 (23) | 1.00 | | | |
| Intubated days | 1 (0–12) | 1 (0–9) | 1 (0–16) | 0.393 | 1 (0–10) | 2 (0–13) | 0.569 | | | |
| Outcome characteristics | | | | | | | | | | |
| Length of ICU stay in days | 16 (10–29) | 15 (7–28) | 16 (12–29) | 0.554 | 14 (7–24) | 16 (11–31) | 0.357 | | | |
| Poor functional outcome at 3 months (mRS > 2) | 19 (32) | 8 (27) | 11 (37) | 0.580 | 7 (23) | 12 (40) | 0.267 | | | |
| Poor functional outcome at 12 months (mRS > 2)² | 10 (20) | 5 (21) | 5 (19) | 1.00 | 4 (16) | 6 (24) | 0.725 | | | |

Significant differences between low and high PGV in univariate analysis (P < 0.05) is given in bold

Data are given in median (IQR), mean ± SEM or N(%)
significantly lower both at baseline ($360 \pm 19 \text{ mm}^3$, $p < 0.001$) and 1-year follow-up ($367 \pm 18 \text{ mm}^3$, $p < 0.001$) in SAH patients as compared to healthy age and sex matched referents ($505 \pm 18 \text{ mm}^3$, Fig. 2). Similarly, the percentage of PGV from TIV ($\text{PGV} / \text{TIV} \times 100$) was lower in SAH patients at baseline (0.0252%, IQR = 0.0166–0.0315, $p < 0.001$) and follow-up (0.0251%, IQR = 0.0181–0.0335, $p < 0.001$) as compared to healthy referents (0.0332%, IQR = 0.0274–0.0421). The ratio of $\text{PGV}_{\text{SAH}} / \text{PGV}_{\text{REF}}$ was 0.69 at baseline and 0.76 at 12 months. Overall, PGV did not change over 1 year in SAH patients ($p = 0.604$). However, in sub-analysis, significant dynamic changes of PGV over 1 year were identified: PGV decreased by $75 \pm 8 \text{ mm}^3$ in 28/60 patients (47%; $405 \pm 27–329 \pm 23 \text{ mm}^3$, $p < 0.001$), increased by $120 \pm 22 \text{ mm}^3$ in 22 patients (37%; $298 \pm 23–418 \pm 36 \text{ mm}^3$, $p < 0.001$) and remained stable in 10 patients (17%; $368 \pm 37–360 \pm 35 \text{ mm}^3$, $p = 0.153$).

PGV in patients with PGV increase at 12 months was not different to healthy referents ($p = 0.062$). $\Delta\text{PGV}$ over 1 year was neither associated with H&H grade ($p = 0.251$) nor with age ($p = 0.091$) or sex ($p = 0.094$). The PGV in all tests was relative to TIV.

### Discussion

The main finding of the present study is that PGV is significantly lower in SAH patients, both at 16 days and 1-year follow-up as compared to age and sex matched healthy referents. The current results also suggest an association between lower PGV and impaired neuropsychological long-term outcome.

To the best of our knowledge this is the first study systematically investigating the volume of the pituitary gland in patients with SAH. Regional and global
Table 2 Neuropsychological test results at 1-year follow-up

| Test                      | N  | Median (IQR) | N (%)       |
|---------------------------|----|--------------|-------------|
|                           |    | Average      | Slightly impaired | Impaired |
| MMSE                      | 49 | 29 (27–29)   | 38 (76)     | NA        | 11 (22)   |
| CLOX                      | 47 | 12 (11–13)   | 37 (79)     | NA        | 10 (21)   |
| Semantic verbal fluency   | 47 | 20 (16–27)   | 37 (79)     | 6 (13)    | 4 (9)     |
| FAB score                 | 47 | 16 (14–18)   | 34 (72)     | 1 (2)     | 12 (26)   |
| Digit span forwards       | 48 | 6 (5–6)      | 32 (67)     | 16 (33)   | –         |
| Digit span backwards      | 48 | 4 (3–5)      | 34 (71)     | 13 (27)   | 1 (2)     |
| Anxiety (HADS-D)          | 43 | 6 (2–9)      | 26 (61)     | 9 (21)    | 8 (19)    |
| Depression (HADS-D)       | 43 | 3 (1–6)      | 35 (81)     | 7 (16)    | 1 (2)     |
| Self-assessment of distractibility | 43 | 51 (40–57)   | 32 (74)     | 11 (26)   | –         |
| Self-assessment of fatigue | 43 | 32 (26–37)   | 30 (70)     | 13 (30)   | –         |
| Self-assessment of motivation | 43 | 25 (21–28)   | 38 (88)     | 5 (12)    | –         |

In each test, impairment was classified in patients scoring below the 10th (slightly impaired) or 2nd percentile (impaired) of age-scaled norms (RWT, WMS, FEDA), or below defined cutoff scores (MMSE, CLOX, HADS). MMSE performance was classified impaired in patients scoring < 27, for the CLOX test a cutoff < 11 was used. The FAB score was scored according to age- and education norms (≥ 16th percentile: average, < 16th and ≥ 5th percentile: slightly impaired, < 5th percentile: impaired). Anxiety and depression were scored as slightly increased when ≥ 8 and increased when ≥ 11.

CLOX clock drawing, FAB Frontal Assessment Battery, FEDA Fragebogen erlebter Defizite der Aufmerksamkeit (German Questionnaire for self-perceived deficits in attention), HADS-D Hospital Anxiety Depression Scale, MMSE mini-mental state, RWT Regensburger Verbal Fluency Test, WMS-R Wechsler Memory Scale revised.

*Patients completing the respective test.
considerable variation across different studies. Clinical manifestations of hypopituitarism may resemble neuropsychological impairments, which are commonly observed after SAH. According to this hypothesis, the extent of PGV decrease was associated with worse motivation as assessed by the FEDA questionnaire in our patients. Mood disorders, anxiety, depression and fatigue substantially diminish long-term quality of life after SAH [2, 40]. Preliminary data also suggest that pituitary dysfunction and specifically growth-hormone (GH) deficiency contribute to poor quality of life, emphasizing on the need of detecting and treating modifiable causes in these patients [5, 9]. Symptoms of GH deficiency also include fatigue as well as impairment of attention and memory [4, 5]. This is of interest, since isolated GH deficit is claimed to be the most common affected axis in SAH patients [7, 8]. Due to the anatomical site with blood supply via the long hypophysial portal system, gonadotrophs and somatotrophs are most vulnerable. It is important to mention that somatotrophs are the predominant cell type of the anterior gland making up approximately 45% of pituitary cells [33]. This may explain the link between decreased volume of the pituitary gland and the association with neuropsychological impairments resembling GH deficiency. We could not find an association between baseline PGV and worse motivation at 1 year but further decrease in PGV may explain at least in some cases late-onset hypopituitarism.

We found a significant association between lower PGV at baseline and the FAB summary score assessed at 1 year after SAH. The FAB provides a useful tool to assess executive dysfunctions in several neurological conditions including Alzheimer’s disease or stroke [29, 41, 42]. As already mentioned, symptoms of GH deficiency involve executive dysfunctions such as impairment of attention and memory [4]. One might speculate that patients with low PGV exhibit some degree of pituitary dysfunction and consequently perform worse in the FAB. This hypothesis is supported by preliminary data of a pilot study conducted in TBI patients suggesting that cognitive impairments may be partially reversible with GH substitution [43]. In contrary, poor performance in the FAB may simply reflect decreased energy levels or poor motivation subsequent to hypopituitarism to complete the testing appropriately. It is very important to emphasize, that our study results do not proof causality based on the experimental design. Still our data would support a carefully designed prospective study to further elaborate on these findings.

Limitations
There are several other limitations that merit attention. First, only patients with baseline and 1-year follow-up MRI-scan were included suggesting a trend toward good-grade patients with favorable outcome. Still, the whole spectrum including all clinical severity grades was represented and it is likely that PGV is even lower in poor-grade SAH patients with worse outcome. Second, we did not systematically measure hormone levels and can therefore not conclude an association between low PGV and pituitary dysfunction. Of all pituitary hormones, only TSH was routinely measured in all patients but was not integrated in the final statistical models as we did not find an association in univariate analysis and a selected view on pituitary hormones would have introduced a selection bias. Low PGV may even not be clinically significant since a large percentage of glandular cells needs to be destructed before clinical hypopituitarism is evident [4]. Moreover, patients were not specifically followed for various symptoms of hypopituitarism. Consequently, our study remains hypothesis generating and needs prospective confirmation. Next, the PGV is relatively small which would entail a huge bias when variability of the quantification of PGV is high. In our study, 2 independent neuroradiologists assessed PGV blinded to clinical data resulting in a high interrater reliability with an ICC of 0.979. Finally, this is a single center study and generalizability is therefore limited.

Conclusion
The current study is the first to demonstrate significantly lower PGVs after SAH compared to healthy referents and reveals dynamic changes of PGV within 1 year. A possible association between low PGV and pituitary dysfunction as well as impaired neuropsychological long-term outcome needs further studies including neuroendocrine hormone measurements.

Author details
1 Department of Neurology, Neurocritical Care Unit, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. 2 Department of Radiology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. 3 Institute of Medical Informatics, UMIT: University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer-Zentrum 1, 6060 Hall, Austria. 4 Department of Neuroradiology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. 5 Department of Neurosurgery, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.

Acknowledgments
Open access funding provided by Austrian Science Fund (FWF). We would like to thank the nursing staff and the entire team of the neurological intensive care unit.

Authors’ Contributions
VR and RH were involved in the study idea and design, data acquisition and analysis, writing and drafting the manuscript. ES quantified the PGV, was involved in the study idea, design, and drafting the manuscript. BI, AL, MK, AS, LL, MG, MTP, CFF, BP, MD, RB, CT, AG and CS were involved in the study idea, data acquisition and drafting the manuscript. The authorship requirements have been met by all authors. All authors read and approved this version of the final manuscript.
This study has received funding from the Austrian Science Fund (FWF) under project number KLI 375 (to RB).

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Approval for this study was granted by the local ethics committee (Medical University of Innsbruck, AM4091-292/46).

Informed consent was obtained from all individual participants included in the study according to local regulations.

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 20 June 2019

References

1. Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635–42.
2. Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid haemorrhage. Stroke. 2010;41(8):e519–36.
3. Kreiter KT, Copeland D, Bernardini GL, et al. Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke. 2002;33(1):200–8.
4. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E. Hypopituitarism. Lancet. 2007;369(9517):1461–70.
5. Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A. Hypothalamic-pituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA. 2007;298(12):1429–38.
6. Kreitschmann-Andermahr I, Poll E, Hutter BO, et al. Quality of life and psychiatric sequelae following aneurysmal subarachnoid haemorrhage: does neuroendocrine dysfunction play a role? Clin Endocrinol (Oxf). 2007;66(6):833–7.
7. Can A, Gross BA, Smith TR, et al. Pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurosurgery. 2016;79(2):253–64.
8. Robba C, Bascicaluppi S, Bragazzi N, et al. Clinical prevalence and outcome impact of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review with meta-analysis. Pitutary. 2016;19(5):522–35.
9. Khatib M, Biljard T, Neggers SJ, et al. Hypopituitarism after subarachnoid haemorrhage, do we know enough? BMC Neurol. 2014;14:205.
10. Mayla B, Newcombe V, Nortje J, et al. Magnetic resonance imaging imaging changes in the pituitary gland following acute traumatic brain injury. Intensive Care Med. 2008;34(3):468–75.
11. Schneider HJ, Samann PG, Schneider M, et al. Pituitary imaging abnormalities in patients with and without hypopituitarism after traumatic brain injury. J Endocrinol Invest. 2007;30(4):R1–12.
12. Kronvall E, Sonesson B, Valdemarsson S, et al. Reduced quality of life in patients with pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a prospective longitudinal study. World Neuropsychiatry. 2016;88:83–91.
13. Vilikki JS, Juvela S, Siironen J, et al. Relationship of local infarctions to cognitive and psychosocial impairments after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2004;55(4):790–802 (discussion 3).
14. Martinaud O, Perin B, Gerardin E, et al. Anatomy of executive deficit following ruptured aneurysm communicating artery aneurysm. Eur J Neurol. 2009;16(5):595–601.
15. Bendel P, Kovisto T, Hanninen T, et al. Subarachnoid hemorrhage is followed by temporomential volume loss: MRI volumetric study. Neuroradiology. 2006;67(4):573–82.
16. Scherfner C, Schiefler AJ, Delazer M, et al. Longitudinal profile of iron accumulation in good-grade subarachnoid hemorrhage. Ann Clin Transl Neurol. 2016;3(10):781–90.
17. Bendel P, Kovisto T, Alka M, et al. Atrophic enlargement of CSF volume after subarachnoid hemorrhage: correlation with neuropsychological outcome. AJNR Am J Neuroradiol. 2010;31(2):370–6.
18. Tam AK, Kapadia A, Llodogwe D, et al. Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage. J Neurol. 2013;119(1):198–206.
19. Bendel P, Kovisto T, Niskanen E, et al. Brain atrophy and neuropsychological outcome after treatment of ruptured anterior cerebral artery aneurysms: a voxel-based morphometric study. Neuroradiology. 2009;51(11):711–22.
20. Steiner T, Juvela S, Unterberg A, et al. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93–112.
21. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711–37.
22. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391–5.
35. Roussel-Gervais A, Couture C, Langlais D, et al. The cables1 gene in glucocorticoid regulation of pituitary corticotrope growth and cushing disease. J Clin Endocrinol Metab. 2016;101(2):513–22.
36. Sahni D, Jit I, Bhansali A. Weight and dimensions of the pituitary in northwestern Indians. Pituitary. 2006;9(1):19–26.
37. Grams AE, Gempt J, Stahl A, Forschler A. Female pituitary size in relation to age and hormonal factors. Neuroendocrinology. 2010;92(2):128–32.
38. Aimaretti G, Ambrosio MR, Di Somma C, et al. Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf). 2004;61(3):320–6.
39. Giritharan S, Cox J, Heal CJ, et al. The prevalence of growth hormone deficiency in survivors of subarachnoid haemorrhage: results from a large single centre study. Pituitary. 2017;20(6):624–34.
40. Visser-Meily JM, Rhebergen ML, Rinkel GJ, van Zandvoort MJ, Post MW. Long-term health-related quality of life after aneurysmal subarachnoid hemorrhage: relationship with psychological symptoms and personality characteristics. Stroke. 2009;40(4):1526–9.
41. Slachevsky A, Villalpando JM, Sarazin M, et al. Frontal assessment battery and differential diagnosis of frontotemporal dementia and Alzheimer disease. Arch Neurol. 2004;61(7):1104–7.
42. Kopp B, Rosser N, Tabeling S, et al. Performance on the frontal assessment battery is sensitive to frontal lobe damage in stroke patients. BMC Neurol. 2013;13:179.
43. High WM Jr, Briones-Galang M, Clark JA, et al. Effect of growth hormone replacement therapy on cognition after traumatic brain injury. J Neurotrauma. 2010;27(9):1565–75.